Scilex Holding Company

SCLX

US80880W1062

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-09-16 EDT			5-day change	1st Jan Change
1.090 ^USD	-5.22%		+6.86%	-46.57%

09-12	Scilex Gets Drug Distributor Accreditation from National Association of Boards of Pharmacy	MT
09-03	Scilex Unit Semnur Pharmaceuticals, Denali Capital Sign Merger Agreement	MT

Scilex Holding Company Provides Preliminary Unaudited Sales Guidance for the Month Ended July 31, 2024

August 01, 2024 at 09:01 am

Scilex Holding Company provided preliminary unaudited sales guidance for the month ended July 31, 2024. For the period, the company expects total product net sales to be in the range of $4.3 million to $5.3 million, compared to $2.8 million for the same period last year, representing growth in the range of approximately 54% to 89%.

Latest news about Scilex Holding Company

Scilex Gets Drug Distributor Accreditation from National Association of Boards of Pharmacy	09-12	MT
Scilex Unit Semnur Pharmaceuticals, Denali Capital Sign Merger Agreement	09-03	MT
Scilex Holding Says US FDA Approves Supplemental New Drug Application for Precision Dosing of Gloperba Label	08-29	MT
Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA Label	08-29	CI
Scilex Says New US Patent to Be Issued for Pain Treatment	08-21	MT
Scilex Signs Deal to Expand Distribution of ZTlido	08-09	MT
Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido in Morocco, Tunisia, Jordan, Iraq, and South Africa	08-09	CI
Denali Capital Acquisition Corp. announced that it expects to receive $0.18 million in funding from Scilex Holding Company	08-08	CI
Scilex Holding Company Provides Preliminary Unaudited Sales Guidance for the Month Ended July 31, 2024	08-01	CI
Scilex Holding Company Appoints Annu Navani as Board of Directors	07-23	CI
Scilex Enters Collaboration With China-Based ACEA	07-17	MT
Scilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics' R&D Expertise and Local Market Connections to Support the Expansion of Ztlido®? Program in Ex-Us and Potentially Provide Additional Access to Patients in Certain Key Markets in Far East Region	07-17	CI
Denali Capital Acquisition Corp. announced that it expects to receive $0.179999 million in funding from Denali Capital Global Investments LLC	07-09	CI
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday	07-03	MT
Top Premarket Gainers	07-03	MT
Scilex Holding Unit Semnur Pharmaceuticals, Denali Capital Acquisition Propose Merger	07-02	MT
Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital	07-02	RE
Semnur Pharmaceuticals, Inc. signed a letter of intent to acquire Denali Capital Acquisition Corp. for approximately $2 billion in a reverse merger transaction.	07-01	CI
Scilex Holding Company Announces Publication in Pain Journal Regarding Phase 3 Results of the Pivotal Registration Trial of Sp-102 (Semdexa?) in Lumbosacral Radicular Pain	06-14	CI
Sector Update: Health Care Stocks Rise Premarket Wednesday	06-12	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Ahead of US FOMC Announcement	06-12	MT
Scilex Holding Signs Commitment Letter for $100 Million Financing; Shares Advance Premarket	06-12	MT
Scilex Holding Company announced that it expects to receive $100 million in funding	06-10	CI
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	06-06	MT
Scilex Shares Advance after FDA Approves Production of Gout Medication	06-06	MT

Chart Scilex Holding Company

Duration

Period

More charts

Company Profile

Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. Its second commercial product ELYXYB, is a potential first-line treatment, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Its product candidates include SP-102 (SEMDEXA), SP-103 and SP-104. SP-102 is a viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica. Its SP-103 is a triple-strength formulation of ZTlido, for the treatment of chronic neck pain.

Employees

113

Sector

Pharmaceuticals

Calendar

2024-11-16 - American College of Rheumatology Convergence Conference

More about the company